Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc. (CKPT) generates frequent news as a commercial-stage immunotherapy and targeted oncology company focused on solid tumor cancers. Company updates center on its FDA-approved product UNLOXCYT™ (cosibelimab-ipdl) for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation, as well as on its investigational EGFR inhibitor olafertinib (formerly CK-101).
News items commonly include regulatory milestones such as FDA acceptance and review of the Biologics License Application (BLA) for cosibelimab, issuance of a complete response letter related to a third-party contract manufacturing organization, BLA resubmission, and eventual FDA approval of UNLOXCYT. Checkpoint also reports on clinical data, including longer-term results from its pivotal cosibelimab trial in locally advanced and metastatic cSCC presented at major oncology meetings.
Investors following CKPT can also expect corporate and financial announcements, such as quarterly and full-year financial results, registered direct offerings and warrant exercises, and cash position updates. Strategic developments feature prominently, including the announced Agreement and Plan of Merger with Sun Pharmaceutical Industries, Inc., under which Checkpoint would become a wholly owned subsidiary of Sun Pharma if closing conditions are satisfied.
Additional news coverage highlights scientific and business collaborations, for example Checkpoint’s collaboration with GC Cell to explore the combined therapeutic potential of cosibelimab with Immuncell-LC, an autologous Cytokine Induced Killer T cell therapy. Conference presentations, such as corporate overviews at investor conferences, also appear in the company’s news flow. For investors and observers interested in immuno-oncology, PD-L1–targeting therapies, and EGFR-driven lung cancer research, the CKPT news page offers an ongoing view into Checkpoint’s regulatory, clinical, financial and strategic developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.